Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments

OBJECTIVE: Although sorafenib, a molecular targeted agent, has survival benefits for advanced hepatocellular carcinoma (HCC) patients, its disease control rate remains limited. To explore the potential for augmenting its antitumor effect, we assessed the preclinical and clinical efficacy and tolerab...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Hiroyuki, Iwamoto, Hideki, Nakano, Masahito, Nakamura, Toru, Masuda, Atsutaka, Sakaue, Takahiko, Tanaka, Toshimitsu, Nakano, Dan, Kuromatsu, Ryoko, Niizeki, Takashi, Okamura, Shusuke, Shimose, Shigeo, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Yano, Hirohisa, Kawaguchi, Atsushi, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363883/
https://www.ncbi.nlm.nih.gov/pubmed/34388691
http://dx.doi.org/10.1016/j.tranon.2021.101201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363883/
https://www.ncbi.nlm.nih.gov/pubmed/34388691
http://dx.doi.org/10.1016/j.tranon.2021.101201

Ejemplares similares